


# Hyaluronic acid nanogel (HA nanogel)

A New Excipient  
Cholesterol substituted hyaluronic acid

New Product Development Office  
Functional Additives Div.  
Specialty Solutions SBU  
Asahi Kasei Co.

# What's HA nanogel



HA nanogel is composed of cholesterol substituted hyaluronic acid (HA), which forms a nano-sized hydrogel particle in water by self-assembly



HA nanogel can host various types of drug molecules via hydrophobic interaction



# Three grades of HA nanogel

**Precipitation Grade:**  
Precipitated in the subcutis





SC injection

**Dispersion Grade:**  
Circulation in the body



IV injection





**Emulsification Grade:**  
Coating the drug particle



Emulsify the drug

# Unique salt-responsive precipitation property


## Solubility of HA nanogel in PBS




# Grades and main targets

Grade	Emulsification Grade	Precipitation grade	Dispersion grade
Main target	Particle surface coating	Sustained release of biologics	Solubilization of poorly water-soluble drugs
MW of HA	5 – 20 kD	25 – 40 kD	5 – 20 kD
DS of cholesterol	5 – 10 unit mol %	10 – 20 unit mol %	30 – 50 unit mol %
Particle size (PDI)	20 – 50 nm (0.3)	50 – 100 nm (0.3)	20 – 50 nm (0.3)
Expected functions	<ul style="list-style-type: none"> <li>■ Emulsification of drug particles</li> </ul>	<ul style="list-style-type: none"> <li>■ <i>In situ</i> depot sustained release</li> <li>■ Retained biological activity</li> <li>■ Inhibition of aggregation</li> <li>■ High loading capacity (20–40 w/w%)</li> </ul>	<ul style="list-style-type: none"> <li>■ Improvement of solubility</li> <li>■ Inhibition of aggregation</li> <li>■ High loading capacity (5–15 w/w%)</li> </ul>

# Key functions of HA nanogel




# Molecular versatility



HA nanogel can load versatile drug molecules such as proteins, peptides, and small molecules

# Easy formulation



Proteins and peptides	Mw	Loading wt%
Exendin-4	4,200	25*
Lysozyme	14,000	29*
Human growth hormone	22,000	23
Carbonic anhydrase	29,000	26
Erythropoietin	34,000	46*
BSA	68,000	29
Conalbumin	75,000	38
Aldolase	158,000	40


\* WO2010-053140

Various drug molecules can be encapsulated by just mixing in water




# Activity retention of protein

HA nanogel solution  
with hGH loading




PBS




Precipitate



HP- $\beta$ -CyD  
(collapse HA nanogel)




Released hGH





Nb2-11 cell

After encapsulation




Before encapsulation



HA nanogel protects proteins from denaturation while retaining full bioactivity

# Sustained release of protein

Plasma PK of hGH after SC




Formulation	hGH	(mg/kg)	0.5	1.5	3	4.5	6
		(Loading %w/w)	-	5	10	15	20
		(mg/mL)	0.1	0.3	0.6	0.9	1.2
	HA nanogel	(mg/mL)	-	6	6	6	6
PK parameters	Cmax	(ng/mL)	99.1	16.8	27.8	58.8	173.2
	AUCinf	(ng hr/mL) <sup>*)</sup>	332	562	970	1711	2963
	MRTinf	(hr)	2.6	58.4	55.7	53.1	66.3
	BA (vs SC)	(%)	-	58.2	50.3	59.1	76.8

hGH was dose-dependently released for 10 days


# Anti-aggregation of protein

HA nanogel/ Conalbumin  
in water  
6mg/mL / 2mg/mL




HA nanogel  
+ Conalbumin

Incubation at 58°C for 12h



Same effect detected for both grades

Conalbumin in water  
2mg/mL



Conalbumin

HA nanogel could protect conalbumin from aggregation caused by thermal denaturation

# Solubility enhancement of poorly-water soluble drugs by HA nanogel

Drug	Mw	Solubility (µg/mL)	Solubility with HA nanogel(µg/mL)	Enhanced solubility (times)
Itraconazole	705	<1	3,800	> 3,800
Cyclosporine A	1,202	30	10,000	> 300

## Comparison of solubilizing effect of HA nanogel with other solubilizers

Solubility of CyA in solubilizer (50mg/mL)

<b>HA nanogel:</b>	<b>10,000</b> µg/mL
Cremophor EL:	1,000 µg/mL *
TW80/TW20:	500 µg/mL *
Cyclodextrins:	100 µg/mL *

\* AAPS PharmSciTec 2001, 2(1), article 2(<http://WWW.pharmscitech.com>)

HA nanogel could improve the solubility of poorly water-soluble drugs

# Competitive features of HA nanogel

Grade	Precipitation grade	Dispersion grade
Main target	Sustained release of protein/peptide drugs	Solubilization of poorly water-soluble drugs
Competitive features	<ul style="list-style-type: none"><li>■ No chemical conjugation necessary (vs. PEGylation)</li><li>■ Applicable for protein (vs. PLGA-MS)</li><li>■ Easy formulation</li><li>■ Aseptic filtration available</li></ul>	<ul style="list-style-type: none"><li>■ Higher solubilizing effect (vs. Cremophor EL, TW80/TW20, CyD)</li><li>■ Applicable for large molecules (vs. CyD)</li><li>■ Safety</li></ul>

Asahi Kasei has produced a new pharmaceutical excipient, HA nanogel



HA nanogel can

- ✓ load various types of drug molecules by just mixing
- ✓ be used as *in situ* depot sustained release formulation with retained drug activity
- ✓ solubilize and inhibit aggregation of drug molecules

We'd like to develop HA nanogel formulation together with pharmaceutical companies

# AsahiKASEI

## *Creating for Tomorrow*

### THE COMMITMENT OF THE ASAHI KASEI GROUP:

To do all that we can in every era to help the people of the world make the most of life and attain fulfillment in living.

Since our founding, we have always been deeply committed to contributing to the development of society, boldly anticipating the emergence of new needs.

This is what we mean by “Creating for Tomorrow.”

